Breaking News, Collaborations & Alliances

Sandoz Enters Biosimilars Deal with Gan & Lee Pharmaceutical in China

Covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sandoz has entered into an agreement with Gan & Lee Pharmaceutical to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes. These medicines are currently in early and clinical stages of development for the EU, U.S. and other territories.   The commercialization and supply agreement with Gan & Lee aims at bringing to market biosimilar versions of glargine, lispro and aspart, the three top insulin medicines by sales. Gan & Lee is a leading in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters